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The Nestin progenitor lineage is the compartment
of origin for pancreatic intraepithelial neoplasia
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To determine the cell compartment in which initial oncogenic
mutations occur in pancreatic ductal adenocarcinoma (PDAC), we
generated a mouse model in which endogenous expression of
mutated Kras (KrasG12D) was initially directed to a population
of pancreatic exocrine progenitors characterized by the expression
of Nestin. Targeting of oncogenic Kras to such a restricted cell
compartment was sufficient for the formation of pancreatic intra-
epithelial neoplasias (PanINs), putative precursors to PDAC. PanINs
appeared with the same grade and frequency as observed when
KrasG12D was targeted to the whole pancreas by a Pdx1-driven Cre
recombinase strategy. Thus, the Nestin cell lineage is highly re-
sponsive to Kras oncogenic activation and may represent the
elusive progenitor population in which PDAC arises.
pancreatic ductal adenocarcinoma  cell of origin  KrasG12D
Pancreatic ductal adenocarcinoma (PDAC) is often charac-terized by local cancer spread and a high prevalence of
metastases at presentation. One reason for the high mortality
rate is the late diagnosis because of the inability to detect the
cancer at early stages (1). Despite the characterization of several
genetic abnormalities in PDAC, the initiating events as well as
the cell of origin that gives rise to PDAC have remained elusive.
It is recognized, however, that activating mutations of the Kras
oncogene are the most frequent (90%) and the earliest genetic
alterations associated with PDAC (2). Moreover, endogenous
expression of a constitutively activated Kras (KrasG12D) allele in
the whole pancreas from its earliest stages of development
through the use of Pdx1- or Ptf1a-driven Cre recombinase
strategy (Pdx1-Cre/LSL-KrasG12D or Ptf1a-Cre/LSL-KrasG12D
mouse models) can induce preinvasive lesions or PanINs, for
pancreatic intraepithelial neoplasia (3, 4). Despite the early
embryonic oncogenic activation of Kras, these mice do not
develop clear lesions until adulthood (2–4 months old), and
metastatic disease is rare and does not occur until late in life (7–8
months) (3). Because this genetic approach leads to the targeting
of mutated Kras to the whole pancreas, it does not allow for the
definition of the specific cell type or cell of origin that would be
particularly responsive to Kras oncogenic mutation. Conversely,
mice displaying ectopic expression of oncogenic Kras in differ-
entiated pancreatic cells (acinar or ductal) exhibit varying de-
grees and types of pancreatic lesions, but they do not progress
through histologically defined PanINs and fail to recapitulate
human PDAC progression (5). These data suggest that a more
restricted population of progenitor cells could constitute the cell
type responsive to Kras oncogenic activation.
We have now generated an animal model in which the
endogenous KrasG12D is specifically activated in the Nestin-
expressing cells, a population of exocrine pancreas progenitor
cells. KrasG12D is subsequently activated in a more restricted
population, the Nestin cell lineage. We now show that the
Nestin-driven compound mutant mice develop mouse PanINs
(mPanINs) in the same spatiotemporal manner as in a Pdx1-
Cre/LSL-KrasG12D model where the Kras mutation is targeted to
the whole pancreas.
Results and Discussion
Nestin Is a Marker of Exocrine Pancreas Progenitor Cells. Nestin, a
general protein marker of progenitor cells (6), is expressed
during pancreas embryonic development (7, 8). Immunohisto-
chemical studies indicate that Nestin is present in mesenchymal
(9) and endothelial cells (10), whereas lineage-tracing experi-
ments indicate that mostly exocrine cells are derived from
Nestin-expressing progenitor cells (7, 8). In vivo, Nestin is not
present in endocrine cells during either embryogenesis or adult-
hood, underscoring the conclusion that endocrine cells do not
derive from Nestin-expressing progenitors (7, 8, 11–15). More-
over, in rodents, Nestin-expressing cells contribute to the regen-
erative capacity of the exocrine pancreas after partial pancrea-
tectomy and during recovery from acute pancreatitis (15, 16).
To confirm the role of Nestin as a marker of exocrine
progenitor cells, we carried out lineage-tracing experiments by
breeding mice that express the Cre recombinase under the
control of Nestin promoter and enhancer-regulatory elements
(17) with the Rosa26 (R26R) mouse line (18). This second
mouse line carries a conditional -galactosidase (LacZ) allele
under the control of a transcription silencing region (Lox-Stop-
Lox or LSL). Briefly, in double-transgenic mice Nestin-Cre/
R26R, the cells that express transiently (or permanently) Nestin
will also express the Cre recombinase. This enzyme will mediate
the excision by homologous recombination of the LSL region
and indirectly activate the expression of LacZ. Because this
activation is an irreversible genetic event, all cells derived from
Nestin-expressing progenitors will maintain LacZ expression. In
adult mice (3–4 months old), a very strong LacZ signal is
observed in acinar cells and some rare ductal cells (Fig. 1 A and
B and data not shown). Although the LacZ signal was much
weaker in 10-day-old mice (data not shown), it was seen in
20–50% of the exocrine pancreas in both age groups, exhibiting
a heterogeneous pattern within each pancreas and between
pancreata. By contrast, LacZ staining in the brain of the
double-transgenic mice was fully penetrant, as evidenced by a
diffuse signal that was reproducibly intense within defined
regions (Fig. 1C).
The Nestin-Cre transgenic strain of mice (17) that we used, where
Cre is under the control of both the promoter and enhancer of the
Nestin gene, has been characterized for Cre expression in both the
pancreas and the central nervous system (7, 17). When bred to the
R26R strain, this mouse displayed LacZ expression at slightly
reduced levels compared with Nestin expression in the early stages
of pancreas development (7). The authors of the study proposed
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that there could be a short delay between Cre expression (under
Nestin-regulatory regions) and the activation of LacZ. Subse-
quently, some early Nestin-expressing populations might not ex-
press LacZ. Another possible explanation for the limited pancreatic
staining could be that the Nestin-Cre transgene has a mosaic
expression in the pancreas, as was observed in the Pdx1-Cre mice
used for the generation of the original Pdx1-Cre/LSL-KrasG12D
animal model (3).
LacZ expression was also observed in some endothelial cells
as shown by the staining of some blood vessels and in some
mesenchymal cells (Fig. 1C and data not shown), as described
previously (7). A few endothelial (PECAM-1-expressing) cells
within the islets also exhibited LacZ staining (data not shown).
However, LacZ staining was absent in the endocrine cells,
confirming the hypothesis (7) that the Nestin-expressing cells are
exclusively progenitors of the exocrine pancreas (both acini and
ducts).
To demonstrate the presence of Nestin-expressing progenitor
cells in the adult pancreas, we used a transgenic mouse line that
expresses green fluorescent protein (GFP) under the control of
the same Nestin-regulatory elements (19). A small population of
GFP-positive cells was present in the acini in the adult pancreas
(Fig. 1D). By contrast, GFP was not present in the endocrine
cells, ducts, or blood vessels but was evident in some discrete
PECAM-1-expressing cells in the islets (Fig. 1D Inset and data
not shown).
Centroacinar cells have been proposed to be the progenitors
in adult pancreas (20). To assess the possibility that the Nestin-
expressing cells are centroacinar cells, we next performed im-
munofluorescence studies to look for the colocalization of Hes-1,
a known centroacinar cell marker (20), with the GFP-expressing
cells. Using three different Hes-1 antibodies, we did not detect
any Hes-1 signal in the GFP-expressing cells (data not shown),
indicating that the adult Nestin-expressing cells are not cen-
troacinar cells. However, this experiment did not rule out the
possibility that centroacinar cells could be derived from embry-
onic Nestin progenitors that no longer expressed Nestin. There-
fore, we next examined the centroacinar cells in LacZ-stained
Nestin-Cre/R26R adult pancreas. As shown in (Fig. 1 E–H), the
centroacinar cells characterized by Hes-1 expression (Fig. 1 E
and F) or Dolichos biflorus agglutinin binding (20) (Fig. 1 G and
H) did not express LacZ, demonstrating that centroacinar cells
are not derived from the Nestin progenitors. This experiment
allowed us to rule out the possibility that in our following model,
centroacinar cells could be the target of transformation events.
Inasmuch as Nestin is up-regulated when acinar cell proliferation
is induced in the pancreas (15, 16) and is expressed in multiple
cultured human pancreatic cancer cell lines (present work; data
not shown), one could propose that Nestin expression is acti-
vated or up-regulated in the pancreas during transformation.
Our following in vivo data strongly suggest that the initial
oncogenic event occurs in Nestin-expressing cells.
Endogenous KrasG12D Expression in the Pancreatic Nestin Cell Lineage
Induces Intraepithelial Neoplasia. To generate a compound mutant
mouse that expresses endogenous KrasG12D in the Nestin cell
lineage, we have bred the mouse line carrying conditionally
expressed mutated KrasG12D allele (3) with the transgenic
Nestin-Cre mouse line (described above). The conditional acti-
vation of KrasG12D depends on the excision by homologous
recombination of an LSL or transcription-silencing region situ-
ated upstream from the transcription initiation site. The condi-
tionally activated Kras has been recombined into its own locus
(knockin) (Fig. 2A). Thus, as is the case in human cancers,
activated KrasG12D remains under the control of its natural
promoter, eliminating any concerns that may arise from ectopic
Kras overexpression, such as induction of cell cycle arrest and
senescence (21). The KrasG12D mutation, commonly found in
human PDAC, results in a glycine to aspartate substitution in the
expressed protein, which compromises both its intrinsic and
extrinsic GTPase activities. Expression of the KrasG12D allele
results in constitutive downstream signaling of Ras effector
pathways. Before breeding with the Nestin-Cre animals, the
LSL-KrasG12D mice carry a functionally null allele of Kras and
are maintained as heterozygous for the wild-type allele. Ho-
mozygosity for the LSL-KrasG12D allele would be equivalent to
Kras complete knockout, which is embryonic-lethal (22). Breed-
Fig. 1. Nestin cell lineage characterization and Nestin expression in the
pancreas. (A–C) LacZ staining showing Nestin cell lineage tracing in Nestin-
Cre/R26R mice. (A and B) Three- to four-month-old pancreas. Strong but
heterogeneous staining is seen the in the acinar cells in some pancreatic
segments, whereas weaker staining is seen in other segments; endothelial
cells within blood vessels exhibit LacZ staining (B, open arrows), indicating
that these cells also derive from Nestin-expressing progenitor cells, in contrast
to the endocrine cells, which are always devoid of LacZ staining (B, star). (C)
Three-month-old brain. All of the cells express LacZ. (D) GFP expression in the
pancreas of a 2-month-old Nestin-GFP mouse is observed in discrete acinar
(arrows) and endothelial/mesenchymal cells (arrowheads) throughout the
pancreatic parenchyma; some endothelial cells (F Inset) within the islets are
GFP-positive, whereas the endocrine cells are always devoid of a GFP signal. (E
and F) Hes-1 immunolabeling on 3-month-old Nestin-Cre/R26R LacZ-stained
pancreas. Note that the Hes-1-labeled cells (light brown, open arrows) are
surrounded by a white ring, showing that they are not LacZ-stained. (G and H)
Serial sections of a LacZ-stained acinus and its associated unstained ductule
(open arrows), with (H) D. biflorus agglutinin staining revealing that the lectin
binds to the duct cells and the centroacinar cells that are clearly devoid of LacZ
staining. (Magnification: A, 200; B, 400; C, 50; D, 400; D Inset, 200;
E–H, 600.)
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ing of the LSL-KrasG12D mice with the Nestin-Cre line generated
animals with a heterozygous condition (Kras/G12D) in the
Nestin cell lineage (Fig. 2 A). The expression of both alleles was
analyzed by RT-PCR/ restriction fragment length polymorphism
(RFLP) in compound mutant tissues knowing that the KrasG12D
allele carries a HindIII restriction site that allows for the
discrimination between wild-type (WT) and KrasG12D messages
(4). Similar levels of KrasG12D and WT Kras were detected in the
brain of the compound mutant animals, whereas no mutant
message was observed in the brain of WT siblings (Fig. 2B). In
the compound mutant pancreas, the predominant message was
KrasG12D message, whereas only WT Kras was detected in WT
pancreas (Fig. 2B). Because we used a nonquantitative PCR
approach, we cannot draw any conclusions as to the relative
amounts of each message in the different tissues, but these data
confirm that KrasG12D is activated in the compound mutant
pancreas.
All of the compound mutant mice Nestin-Cre/LSL-KrasG12D
developed pancreatic neoplasia (mPanINs) with close to 100%
penetrance (1 mouse of 14 did not present pancreatic lesions). In
2-month-old animals, PanIN 1-A were observed, characterized
by transition from normal cuboidal morphology to a columnar
phenotype, nuclear crowding (Fig. 2Ci) and in some cases
abundant supranuclear, mucin-containing cytoplasm (Fig. 2Cii).
However, the polarity of the cells was maintained with basally
located nuclei, and nuclear atypia, when seen at all, was minimal.
Rare mPanIN 1-B characterized by papillary or micropapillary
ductal lesions without significant loss of polarity or nuclear
atypia were also observed. mPanIN 1-B were more abundant by
4 months (Fig. 2Civ). Although there were usually two to four
Fig. 2. Conditional activation of Kras in the Nestin cell lineage is sufficient for generating mPanINs. (A) Breeding strategy of LSL-KrasG12D mice with Nestin-Cre
mice. The Cre recombinase expressed under the control of Nestin-regulatory elements will mediate the recombination/excision of the LSL specifically in the
Nestin-expressing cells. Subsequently, Kras will be conditionally activated only in the Nestin cell lineage. (B) RT-PCR/RFLP was performed on a 4-month-old
pancreas and brain to confirm KrasG12D expression based on a KrasG12D allele-specific HindIII site. PCR-amplified cDNA was undigested () or digested () with
HindIII, generating the mutant amplicon that migrates as the lower band in relation to the wild-type product. Lanes 1 and 2 are Nestin-Cre/LSL-KrasG12D (KxN)
brain cDNAs, lanes 3 and 4 are wild-type brain cDNAs, lanes 5 and 6 are wild-type pancreas cDNAs, and lanes 7 and 8 are KxN pancreas cDNAs. There are similar
levels of wild-type and mutated Kras products in the brain, whereas there is a preponderance of the mutated allele in the pancreas in 5 of 5 mutant mice. (C)
mPanINs in Nestin-Cre/LSL-KrasG12D compound mutant mice. (Ci and Cii) Two-month-old pancreas. (Ci) Focus of PanINs1-A. (Cii) Normal ducts (arrowheads) can
be observed next to a PanIN1-B (12). (Ciii–Cvi) Four-month-old pancreas. (Ciii) Isolated PanINs (arrows) can be observed, but the acini and the islets (star) are not
affected. (Civ and Cv) PanIN1-B, where the transition between normal (arrowheads) and abnormal ductal epithelium is clearly observed. (Cvi) multiple PanIN foci
are observed. (Magnification: Ci, Cii, Civ, and Cv, 400; Ciii and Cvi, 200.)














qmPanINs foci per section, occasionally multiple foci were
present (Fig. 2Cvi). Overall, the structure of the pancreas in the
Nestin-Cre/LSL-KrasG12D mice appeared normal (Fig. 2Ciii). As
observed in human pancreatic cancer, (i) all lesions present at 2
months appeared to have a clear ductal origin (no acinar–ductal
metaplasia observed at this stage); (ii) strong inflammatory
reactions surrounded many of the mPanINs; and (iii) the devel-
opment of these lesions was restricted to the periphery of the
pancreas, and only smaller ducts were affected, whereas larger
ducts appeared normal. In 6-month-old mice, the mutant pan-
creata contained multiple ductal lesions, but there was no clear
progression to more aggressive lesions.
Conditional Activation of KrasG12D in the Nestin Cell Lineage Versus
the Whole Pancreas Generates a Similar Phenotype. To determine
whether the pancreatic Nestin cell lineage is the cell lineage
responsive to KrasG12D activation, we have also generated Pdx1-
Cre/LSL-KrasG12D compound mutant mice where oncogenic
Kras activation is initially targeted to early pancreatic progen-
itors and subsequently to the whole pancreas. The Pdx1-Cre
mouse line used for this work displays full pancreas expression
(23, 24), and the compound mutant mice generated by breeding
these Pdx1-Cre mice with the LSL-KrasG12D mice are thus
similar to the Ptf1a-Cre/LSL-KrasG12D mice (3). We conducted
a parallel analysis of both models. A blind histological analysis
at 4 months in four mutant mice of each genotype demonstrated
that it was not possible to discriminate between the two models.
mPanINs appeared in similar number and type, and limited
acinar–ductal metaplasia was observed in both cases. The epi-
thelial nature of the lesions was confirmed by CK19 staining
(Fig. 3A) and was consistent with what was described in human
PanINs, with a robust accumulation of mucus in the lesions as
evidenced by intense alcian blue staining (Fig. 3B) and the
presence of the mucin-specific protein MUC-5 (Fig. 3C). In
addition, there was increased labeling of the proliferation
marker Ki67 in the PanINs and the surrounding inflammatory
cells (Fig. 3D) and high expression levels of Gli3 and Smooth-
ened (Fig. 3F and data not shown), respectively, a downstream
target and a receptor of hedgehog (25).
It is interesting to note that the hedgehog signaling pathway
was also activated in the acinar and inflammatory cells adjacent
to the lesions (Fig. 3F), whereas no labeling is observed in
normal pancreas. By contrast, Cox2 staining was confined to the
histologically abnormal cells within the PanINs (Fig. 3E). Al-
though Kras is classically known for activating the Raf/ERK,
phosphatidylinositol 3-kinase, and Ral pathways, Cox2 is also
known to be up-regulated by oncogenic Kras and to contribute
to cancer initiation and progression while promoting angiogen-
esis and inflammation (26–28). The highly restricted expression
of Cox2 in the neoplastic part of the ducts at very early stages of
lesion formation suggests that it may be a major downstream
mediator of oncogenic Kras with respect to PanIN initiation.
Our data thus confirm that Nestin-Cre/LSL-KrasG12D mice
develop pancreatic lesions that exhibit the histological features
of early human PanINs, that the Nestin cell lineage in the
pancreas is the candidate cellular compartment for the devel-
opment of pancreatic neoplasia, and that this mouse model could
Fig. 3. Characterization of PanINs in 4-month-old Nestin-Cre/LSL-KrasG12D pan-
creas. (A) CK19 staining confirms the epithelial origin of the PanINs. (B) Alcian
blue staining reveals the abundant mucin content of the lesions as confirmed by
strong Muc5a immunoreactivity (C), a high level of Ki67 observed in PanIN 1-A
and surrounding inflammatory cells (arrowheads) but no staining observed in
adjacent normal acini (D), Cox2 expression limited to the abnormal areas of the
ductal epithelium (arrows) (E), but Gli3 (F) staining the nuclei of all of the cells in
the PanINs as well as in the adjacent inflammatory (solid arrowheads) and some
acinar (open arrowheads) cells. (Magnification: 400.)
Fig. 4. KrasG12D targeting to the Nestin cell lineage generates a more specific
model for PanINs formation. (A) Less acinar–ductal metaplasia observed at 6
months in the pancreas of Nestin-Cre/LSL-KrasG12D mutants as shown by
comparison of CK19 staining between Nestin-Cre/LSL-KrasG12D (A1) and Pdx1-
Cre/LSL-KrasG12D (A2) pancreas. Note the abundance of acinar-like structures
that stain for CK19 in the Pdx1-Cre/LSL-KrasG12D pancreas, next to normal ducts
(arrowhead). (B) Cell lineages determination model. During pancreas devel-
opment, multiple progenitor populations with progressively more restricted
differentiation potential are generated. We propose that the progenitor
population characterized by Nestin expression (in gray) specifically gives rise
to exocrine pancreas; that in the adult pancreas, the Nestin-expressing cells
function as adult progenitor cells; and that this cell population could be the
cell of origin for PDAC.
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prove useful in testing various chemopreventive strategies tar-
geted at PanIN lesions.
Reduced Acinar–Ductal Metaplasia at 6 Months in Nestin-Cre/LSL-
KrasG12D Versus Pdx1-Cre/LSL-KrasG12D Pancreata. By 6 months of
age, only mPanINs 1-A and B were detected in the pancreas of
both mouse models. However, the pancreas in the Pdx1-Cre/
LSL-KrasG12D mice exhibited extensive acinar–ductal metapla-
sia, a phenomenon that has also now been observed in another
laboratory using the Pdx1-Cre/LSL-KrasG12D model (S. F.
Konieczny, personal communication). By contrast, there was
little or no metaplasia in the Nestin-Cre/LSL-KrasG12D pancreas
(Fig. 4A), as demonstrated by blind scoring of sections of four
Nestin-Cre/LSL-KrasG12D and four Pdx1-Cre/LSL-KrasG12D
pancreata. Although the pancreata in the Nestin-Cre/LSL-
KrasG12D model were smaller than in the Pdx1-Cre/LSL-
KrasG12D model, the same blinded analysis revealed that Nestin-
Cre/LSL-KrasG12D mice harbored more free-standing PanINs. It
is known that when KrasG12D is targeted to differentiated
pancreatic cells, prominent acinar–ductal metaplasia is ob-
served, with subsequent development of acinar cell carcinomas
(5). One possible explanation for the extensive acinar–ductal
metaplasia observed in the Pdx1-Cre/LSL-KrasG12D pancreas
could be that oncogenic Kras is activated in a higher number of
differentiated cells. By contrast, the limited acinar–ductal meta-
plasia in the Nestin-Cre/LSL-KrasG12D model may be a reflec-
tion of the more restricted targeting of the oncogene.
We did not observe formation of advanced PanINs or invasive
cancer at 6 months in either model. Because all cells of the
central nervous system are derived from Nestin-expressing pro-
genitors, the Nestin-Cre/LSL-KrasG12D mice have massive acti-
vation of KrasG12D in their central nervous system, and their
survival drops dramatically after 6 months, most likely because
of multiple neurological problems.
Conclusion
Our data demonstrate that activation of oncogenic Kras in the
Nestin cell lineage is sufficient for the initiation of premalignant
PanIN lesions in the pancreas. The formation of lesions occurs
initially with the same frequency as that observed when mutated
Kras is targeted to the whole pancreas. As in a Pdx1-Cre/LSL-
KrasG12D model, the lesions form only in adult animals. These
observations suggest that the initial oncogenic lesion in the
pancreas could occur in a cell type that maintains proliferative
properties and has the capacity to acquire additional mutations,
potentially a progenitor cell. Pancreatic embryonic Nestin-
expressing progenitors give rise to part of the exocrine pancreas,
but targeting of oncogenic Kras to differentiated acinar or ductal
does not generate PanIN-like lesions, indicating that there may
be an undifferentiated Nestin-expressing cell population that
would be sensitive/responsive to Kras oncogenic activation. The
facts that there are Nestin-expressing cells in the adult pancreas
and that this population can transiently expand when prolifer-
ation is induced in the pancreas strongly suggest that these cells
could be adult progenitors. By contrast, our data demonstrate
that centroacinar cells are not derived from Nestin-expressing
cells, ruling out the possibility that centroacinar cells give rise to
PanINs in our model. We propose that the adult Nestin-
expressing cells are the cells of origin for PDAC (Fig. 4B). An
extensive characterization of these cells as well as the targeting
of oncogenic Kras to the adult Nestin-expressing cell compart-
ment will give a definitive answer.
Materials and Methods
Mouse Colony Generation. The LSL-KrasG12D (01XJ6-B6;129-
Kras2tm4Tyj) mice were obtained from the Mouse Models of Human
Cancers Consortium (National Cancer Institute, Frederick, MD).
The R26R mice [B6.129S4-Gt(ROSA)26SortmSor/J] and the Nestin-
Cre mice [B6.Cg-Tg(Nes-cre)1Kln/J] were purchased from The
Jackson Laboratory (Bar Harbor, ME). The Pdx1-Cre mice were
kindly provided by G. Gu (23). The Nestin-GFP mice were a
generous gift from Gregori Enikolopov (29). All genotyping was
done by PCR following the conditions of the providers.
Histology and Immunohistochemistry. Nestin-Cre/LSL-KrasG12D
and Pdx1-Cre/ LSL-KrasG12D mice were perfused with PBS then
10% (wt/vol) formalin. The tissues were dissected, fixed over-
night, and embedded in paraffin. Nestin-Cre/R26R and Nestin-
GFP tissues were briefly fixed in 10% formalin, cryopreserved
in PBS/30% (wt/vol) sucrose, and cryoembedded in OCT com-
pound. For immunostaining, if required, antigen-unmasking
solution (Vector Laboratories, Burlingame, CA) was used ac-
cording to the manufacturer’s instructions. The proteinase K
procedure was used for CK19 staining. Immunostaining proce-
dures were as described in ref. 4. The antibodies and dilution
used were TromaIII (CK19 antibody developed by Rolf Kemler
and obtained from the Developmental Studies Hybridoma Bank,
Iowa City, IA), 1:10; Muc5a (Novocastra, Newcastle upon Tyne,
U.K.), 1:30; Ki67 (Novocastra), 1:200; Gli3 and Smo (Santa Cruz
Biotechnology, Santa Cruz, CA), 1:50; Hes1 (Chemicon, Te-
mecula, CA; T. Sudo, Toray Industries, Inc.; N. Brown, Cincin-
nati Children’s Hospital Medical Center; all used at respective
dilutions of 1:200, 1:500, and 1:400). Alcian blue and LacZ
staining were done as described in ref. 7 and www.ihcworld.com.
RT-PCR/RFLP was done as described previously (4). D. biflorus
agglutinin (Vector Laboratories) staining was done as described
in ref. 20.
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